


## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9578003/publications.pdf Version: 2024-02-01



V10 V10

#	Article	IF	CITATIONS
1	Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma. Frontiers in Immunology, 2016, 7, 690.	4.8	150
2	PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells. Oncolmmunology, 2017, 6, e1284722.	4.6	87
3	Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer. Journal of Hematology and Oncology, 2019, 12, 18.	17.0	79
4	Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells. Journal of Hematology and Oncology, 2017, 10, 68.	17.0	70
5	The differential protein and lipid compositions of noncaveolar lipid microdomains and caveolae. Cell Research, 2009, 19, 497-506.	12.0	57
6	Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy. MAbs, 2018, 10, 1301-1311.	5.2	57
7	Quantitative evaluation of the immunodeficiency of a mouse strain by tumor engraftments. Journal of Hematology and Oncology, 2015, 8, 59.	17.0	43
8	Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth. Biomarker Research, 2020, 8, 19.	6.8	42
9	Myeloid-derived suppressor cells promote lung cancer metastasis by CCL11 to activate ERK and AKT signaling and induce epithelial-mesenchymal transition in tumor cells. Oncogene, 2021, 40, 1476-1489.	5.9	39
10	ANGPTL7 regulates the expansion and repopulation of human hematopoietic stem and progenitor cells. Haematologica, 2015, 100, 585-594.	3.5	38
11	Genome-wide analyses identify KLF4 as an important negative regulator in T-cell acute lymphoblastic leukemia through directly inhibiting T-cell associated genes. Molecular Cancer, 2015, 14, 26.	19.2	27
12	IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cells. Leukemia, 2021, 35, 1380-1391.	7.2	26
13	DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells. Oncolmmunology, 2019, 8, e1509173.	4.6	23
14	PSCA is a target of chimeric antigen receptor T cells in gastric cancer. Biomarker Research, 2020, 8, 3.	6.8	23
15	Loss of Angiopoietin-like 7 diminishes the regeneration capacity of hematopoietic stem and progenitor cells. Journal of Hematology and Oncology, 2015, 8, 7.	17.0	21
16	Effective elimination of adult B-lineage acute lymphoblastic leukemia by disulfiram/copper complex <i>in vitro</i> and <i>in vivo</i> in patient-derived xenograft models. Oncotarget, 2016, 7, 82200-82212.	1.8	17
17	GZD824 suppresses the growth of human B cell precursor acute lymphoblastic leukemia cells by inhibiting the SRC kinase and PI3K/AKT pathways. Oncotarget, 2017, 8, 87002-87015.	1.8	16
18	Heterogeneity of CD34 and CD38 expression in acute B lymphoblastic leukemia cells is reversible and not hierarchically organized. Journal of Hematology and Oncology, 2016, 9, 94.	17.0	15

ΥΑΟ ΥΑΟ

#	Article	IF	CITATIONS
19	CRISPR/Cas9-Mediated Deletion of Foxn1 in NOD/SCID/IL2rgâ^'/â^' Mice Results in Severe Immunodeficiency. Scientific Reports, 2017, 7, 7720.	3.3	12
20	Tissue-based metabolomics reveals metabolic biomarkers and potential therapeutic targets for esophageal squamous cell carcinoma. Journal of Pharmaceutical and Biomedical Analysis, 2021, 197, 113937.	2.8	10
21	Chimeric CTLA4-CD28-CD3z T Cells Potentiate Antitumor Activity Against CD80/CD86–Positive B Cell Malignancies. Frontiers in Immunology, 2021, 12, 642528.	4.8	10
22	Defined, serum/feeder-free conditions for expansion and drug screening of primary B-acute lymphoblastic leukemia. Oncotarget, 2017, 8, 106382-106392.	1.8	7
23	CD215+ Myeloid Cells Respond to Interleukin 15 Stimulation and Promote Tumor Progression. Frontiers in Immunology, 2017, 8, 1713.	4.8	6
24	Transforming primary human hepatocytes into hepatocellular carcinoma with genetically defined factors. EMBO Reports, 2022, , e54275.	4.5	5
25	Human induced-T-to-natural killer cells have potent anti-tumour activities. Biomarker Research, 2022, 10, 13.	6.8	4
26	DAP10 integration in CAR-T cells enhances the killing of heterogeneous tumors by harnessing endogenous NKG2D. Molecular Therapy - Oncolytics, 2022, 26, 15-26.	4.4	3
27	The Chemokine Receptor CCR8 Is a Target of Chimeric Antigen T Cells for Treating T Cell Malignancies. Frontiers in Immunology, 2022, 13, .	4.8	1